Effect of Anti-IgE Therapy in Patients with Peanut Allergy | Zendy

Donald Y.M. Leung | Zendy; Hugh A. Sampson | Zendy; John W. Yunginger | Zendy; A. Wesley Burks | Zendy; Lynda C. Schneider | Zendy; Cornelis H. Wortel | Zendy; Frances M. Davis | Zendy; John D. Hyun | Zendy; William Shanahan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Anti-IgE Therapy in Patients with Peanut Allergy

Author(s) -

Donald Y.M. Leung,

Hugh A. Sampson,

John W. Yunginger,

A. Wesley Burks,

Lynda C. Schneider,

Cornelis H. Wortel,

Frances M. Davis,

John D. Hyun,

William Shanahan

Publication year - 2003

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa022613

Subject(s) - medicine , placebo , anaphylaxis , immunoglobulin e , peanut allergy , food allergy , double blind , antibody , adverse effect , allergy , gastroenterology , immunology , pathology , alternative medicine

Peanut-induced anaphylaxis is an IgE-mediated condition that is estimated to affect 1.5 million people and cause 50 to 100 deaths per year in the United States. TNX-901 is a humanized IgG1 monoclonal antibody against IgE that recognizes and masks an epitope in the CH3 region of IgE responsible for binding to the high-affinity Fc(epsilon) receptor on mast cells and basophils.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research